Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 2
1973 4
1974 2
1975 4
1976 2
1978 6
1979 1
1980 3
1981 3
1982 6
1983 7
1984 4
1985 1
1986 4
1987 5
1988 4
1989 7
1990 9
1991 4
1992 4
1993 5
1994 5
1995 12
1996 5
1997 3
1998 6
1999 3
2000 5
2001 4
2002 3
2006 1
2014 1
2015 1
2017 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Results by year

Filters applied: . Clear all
Page 1
Lipid-lowering agents in proteinuric diseases.
Appel GB, Appel AS. Appel GB, et al. Am J Nephrol. 1990;10 Suppl 1:110-5. doi: 10.1159/000168204. Am J Nephrol. 1990. PMID: 2256470 Review.
Recent trials with lipid-lowering medications have been successful without major side effects. The bile acid sequestrants colestipol and cholestyramine bind bile acids in the gut and deplete the hepatic cholesterol pool, thus inducing LDL hepatocyte receptors. ...
Recent trials with lipid-lowering medications have been successful without major side effects. The bile acid sequestrants colestipol
Adverse effects of hypolipidaemic drugs.
Knodel LC, Talbert RL. Knodel LC, et al. Med Toxicol. 1987 Jan-Feb;2(1):10-32. doi: 10.1007/BF03259858. Med Toxicol. 1987. PMID: 3547004 Review.
Cholestyramine, colestipol, clofibrate, gemfibrozil, nicotinic acid (niacin), probucol, neomycin, and dextrothyroxine are the most commonly used drugs in the treatment of hyperlipoproteinaemic disorders. ...
Cholestyramine, colestipol, clofibrate, gemfibrozil, nicotinic acid (niacin), probucol, neomycin, and dextrothyroxine are the most co …
The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients.
Insull W Jr, Davidson MH, Demke DM, Dujovne CA, Eckert SM, Ginsberg D, Goldberg AC, Hodis HN, Hughes TA, Kane JP, et al. Insull W Jr, et al. Atherosclerosis. 1995 Jan 20;112(2):223-35. doi: 10.1016/0021-9150(94)05418-i. Atherosclerosis. 1995. PMID: 7772081 Clinical Trial.
The purpose of this study was to investigate and compare the efficacy, safety, and patient acceptability of a new formulation of colestipol, colestipol tablets (T), with those of colestipol granules (G), in a randomized, double-blind, placebo-controlled, mult …
The purpose of this study was to investigate and compare the efficacy, safety, and patient acceptability of a new formulation of colestip
Management of lipids in primary and secondary prevention of cardiovascular diseases.
Lavie CJ, Gau GT, Squires RW, Kottke BA. Lavie CJ, et al. Mayo Clin Proc. 1988 Jun;63(6):605-21. doi: 10.1016/s0025-6196(12)64891-5. Mayo Clin Proc. 1988. PMID: 3287024 Review.
In addition, we discuss data that address the premise that reducing low-density lipoprotein cholesterol or raising high-density lipoprotein cholesterol should decrease the progression of coronary atherosclerosis, and we summarize drug trials in which clofibrate, niacin, cholestyr …
In addition, we discuss data that address the premise that reducing low-density lipoprotein cholesterol or raising high-density lipoprotein …
Management of blood lipid abnormalities in coronary heart disease patients.
Kuo PT. Kuo PT. Clin Cardiol. 1989 Oct;12(10):553-60. doi: 10.1002/clc.4960121002. Clin Cardiol. 1989. PMID: 2680196 Free article. Review.
Some recent developments in the field may include the use of: (1) colestipol-niacin to control hypercholesterolemia and induce regression of coronary atherosclerosis; (2) limited amounts of foods rich in stearic or oleic fatty acids to enhance the appeal of cholesterol-low …
Some recent developments in the field may include the use of: (1) colestipol-niacin to control hypercholesterolemia and induce regres …
Combination drug therapy for familial combined hyperlipidemia.
East C, Bilheimer DW, Grundy SM. East C, et al. Ann Intern Med. 1988 Jul 1;109(1):25-32. doi: 10.7326/0003-4819-109-1-25. Ann Intern Med. 1988. PMID: 3288029 Clinical Trial.
STUDY OBJECTIVE: To compare the efficacy of gemfibrozil and colestipol with gemfibrozil and lovastatin in patients with familial combined hyperlipidemia. ...Addition of either colestipol or lovastatin reduced LDL-cholesterol levels by 17% and 25%, respectively, comp …
STUDY OBJECTIVE: To compare the efficacy of gemfibrozil and colestipol with gemfibrozil and lovastatin in patients with familial comb …
Review of clinical studies of bile acid sequestrants for lowering plasma lipid levels.
LaRosa J. LaRosa J. Cardiology. 1989;76 Suppl 1:55-61; discussion 61-4. doi: 10.1159/000174547. Cardiology. 1989. PMID: 2653624 Review.
Both alone and in combination with other lipid-lowering drugs, the bile acid sequestrants cholestyramine and colestipol, are excellent agents for lowering circulating low-density lipoprotein (LDL) cholesterol levels. ...
Both alone and in combination with other lipid-lowering drugs, the bile acid sequestrants cholestyramine and colestipol, are excellen …
Low-dose colestipol plus probucol for hypercholesterolemia.
Dujovne CA, Chernoff SB, Krehbiel P, Jackson B, DeCoursey S, Taylor H. Dujovne CA, et al. Am J Cardiol. 1984 Jun 1;53(11):1514-8. doi: 10.1016/0002-9149(84)90570-8. Am J Cardiol. 1984. PMID: 6375337 Clinical Trial.
The hypocholesterolemic and adverse effects of colestipol, 20 g/day, and colestipol, 10 g/day combined with probucol, 1 g/day, were compared. ...Probucol-colestipol co-administration allowed a 50% reduction in the colestipol dosage, with similar effica …
The hypocholesterolemic and adverse effects of colestipol, 20 g/day, and colestipol, 10 g/day combined with probucol, 1 g/day, …
Comparison of the effects of colestipol hydrochloride and clofibrate on plasma lipids and lipoproteins in the treatment of hypercholesterolemia.
Seplowitz AH, Smith FR, Berns L, Eder HA, Goodman DS. Seplowitz AH, et al. Atherosclerosis. 1981 Apr;39(1):35-43. doi: 10.1016/0021-9150(81)90086-1. Atherosclerosis. 1981. PMID: 7018502 Clinical Trial.
The colestipol group received both colestipol and clofibrate during months 7 through 9 of the study. ...A significant difference was not observed between the effects of 15 g/day of colestipol and those of the higher doses studies. Addition of clofibrate to …
The colestipol group received both colestipol and clofibrate during months 7 through 9 of the study. ...A significant differen …
Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia.
Spence JD, Huff MW, Heidenheim P, Viswanatha A, Munoz C, Lindsay R, Wolfe B, Mills D. Spence JD, et al. Ann Intern Med. 1995 Oct 1;123(7):493-9. doi: 10.7326/0003-4819-123-7-199510010-00003. Ann Intern Med. 1995. PMID: 7661492 Clinical Trial.
OBJECTIVE: To test whether combining psyllium mucilloid with half the usual dose of colestipol reduces the adverse effects associated with colestipol and maintains or increases its efficacy in the treatment of hyperlipidemia. ...The combination therapy and colest
OBJECTIVE: To test whether combining psyllium mucilloid with half the usual dose of colestipol reduces the adverse effects associated …
138 results